A new blueprint for the rational design of siRNA drugs For the first time, researchers imaged a human protein essential to the RNA interference process and found ways to design better siRNA drugs. Written byAllison Whitten, PhD

A new blueprint for the rational design of siRNA drugs For the first time, researchers imaged a human protein essential to the RNA interference process and found ways to design better siRNA drugs. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-new-blueprint-for-the-rational-design-of-sirna-drugs-17296?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_8FqU5l4UXH7xA7y7xND1dOWXaaGbCkGgQWZPBEmH3TqxmpWDa8zLKC7houKjjgDRqf159BsDlRsXA-8lqFVlXC7Xq6A&_hsmi=444660716&utm_content=444660716&utm_source=hs_email Small interfering RNA (siRNA) drugs take advantage of RNA interference (RNAi) to “silence” genes with major advantages: They can target any gene without changing its underlying DNA. But designing these drugs has been difficult because so many different sequences of siRNA must be tested to find out which one works best to silence the target. So far, drug developers have been in the dark about why certain siRNA sequences work so much better than others, or how to predict which ones will be successful.